Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis and pulmonary embolism. Tinzaparin sodium is the only low molecular weight heparin shown to be safe in pregnancy and in critically ill people with renal failure at both treatment and prophylaxis dose levels.
It can be given subcutaneously by syringe, or intravenously. It was manufactured by Leo pharmaceutical company, who withdrew the product from the US in 2011 due to low sales and a contamination issue.

Appearance and properties: white or white crystalline powder

Density: 2.18g /cm3

Boiling point: 644.9oC at 760mmHg

Flash point: 343.8oC

Refractive index: 1.711

Stability: Hygroscopic; ampuled solution may be stored at room temperature for at least 12 mo sodium salt.

Storage conditions: Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials,  ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.